Veterinary Clostridium Vaccine Market by 2023: Growth Opportunities

Posted by vinit sawant on April 27th, 2021

Market Highlights

The increasing awareness pertaining to zoonotic diseases, rising incidence rate of clostridium family diseases, increased awareness relating animal-derived products, and increase in disposable income are expected to drive the growth of market. However, side effects associated with vaccines and high cost of the treatment hamper the market growth over the forecast period.

The veterinary clostridium vaccine market size value of USD 461.7 million in 2017 and is projected to grow at a CAGR of 4.5% over the forecast period.

Segmentation

The global veterinary clostridium vaccine market has been segmented into animal type and distribution channels.

Based on animal type, veterinary clostridium vaccine market is segmented into bovine, ovine, swine, caprine, poultry, and others. The bovine segment is expected to account for the largest share segment of the veterinary clostridium vaccine market in 2017.

Based on distribution channels, veterinary clostridium vaccine market is segmented into veterinary hospital, veterinary clinic, veterinary research institute, and retail pharmacy. The veterinary hospital segment is expected to account for the largest share segment of the veterinary clostridium vaccine market in 2017.

Key Players

Some of the prominent players in the global veterinary clostridium vaccine market are Merck & Co., Inc. (US), Ceva Santé Animale (France), Boehringer Ingelheim International GmbH (Germany), Colorado Serum Company (US), Virbac (Australia), Valneva SE (France), Zoetis (US), Elanco Animal Health (US), and Bayer AG (Germany).